Gosset Ownership
Private
Employees
~20
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Neurenati Therapeutics General Information
Neurenati’s lead program, NEU-001, is a first-in-class, intrarectal combination therapy using a neurotrophic growth factor to regenerate the enteric nervous system in children with Hirschsprung disease. The company has received both Orphan Drug and Rare Pediatric Disease Designations from the US FDA for NEU-001. IND-enabling preclinical work is ongoing, with plans to initiate clinical trials by late 2025 or early 2026. The goal is to provide a non-surgical curative option that could eliminate the need for invasive surgery and reduce lifelong complications associated with current treatments[1][5][6].
Contact Information
Drug Pipeline
NEU-001
Pre-clinicalKey Partnerships
CQDM-SynergiQc grant support[5], Axelys (IP/licensing management and business coaching)[5]
Neurenati Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Mar 5, 2025 | $1.7M | Completed | Preclinical |
To view Neurenati Therapeutics's complete valuation and funding history, request access »